The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...

Boehringer Ingelheim focuses on targeting the proteins involved in this process as a promising strategy for developing new cancer treatments. Credit: Tada Images/Shutterstock. Boehringer Ingelheim and ...

Under development at German family-owned pharma major Boehringer Ingelheim, survodutide is a dual glucagon/GLP-1 receptor agonist for the treatment of adults living with non-cirrhotic metabolic ...

IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) (“Reneo”) today announced the results of the special meeting of its stockholders held on September ...

With the business potentially at an important milestone, we thought we'd take a closer look at Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) future prospects. Aurinia Pharmaceuticals Inc., a ...

The Angelika Amon research building is named after a Viennese pioneer in cell biology who was closely connected with Boehringer Ingelheim. Image credit: Boehringer Ingelheim. Boehringer Ingelheim has ...

Potential launches from new challengers could start in 2026 with Boehringer Ingelheim and Zealand’s survodutide. Several launches in 2027 (Amgen, Altimmune), 2028 (Pfizer, Roche, Viking ...

By Andrew Pollack Hikma Pharmaceuticals agreed to pay about $2.65 billion in cash and shares for Boehringer Ingelheim’s generic drugs business in the United States. Boehringer Ingelheim said ...

The Boehringer Ingelheim Vetmedica FLEXcombo injection package protects pigs against porcine circovirus type 2 and each FLEXCombo package contains a 250 milliliter bottle of Ingelvac CircoFLEX and 250 ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

German drugmaker Boehringer Ingelheim has sold an artificial intelligence ... the software "can help a pharmaceutical company understand the whole network of how diseases, comorbidities, effects ...